Efectividad de la válvula de Ahmed® implantada vía pars plana en pacientes con glaucoma refractario

Q3 Medicine

Archivos De La Sociedad Espanola De Oftalmologia Pub Date : 2024-10-01 DOI:10.1016/j.oftal.2024.05.007

{"title":"Efectividad de la válvula de Ahmed® implantada vía pars plana en pacientes con glaucoma refractario","authors":"","doi":"10.1016/j.oftal.2024.05.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the success rate and complications of the Ahmed® FP7 valve implanted via Pars Plana in a group of vitrectomized patients with refractory glaucoma and anterior segment abnormalities from January 2018 to June 2023.</div></div><div><h3>Methods</h3><div>Quasi-experimental, prospective study. Eleven eyes with refractory glaucoma were included. Participants underwent a comprehensive ophthalmic examination, including assessment of intraocular pressure (IOP) reduction, visual acuity, characterization of glaucoma type, and number of antiglaucoma medications.</div></div><div><h3>Results</h3><div>The mean baseline IOP was 37.3±11mmHg, which decreased to 13.5±3.0mmHg after one year. The qualified success rate was 63.7%, while the complete success rate was 36.3%. The most common diagnosis was neovascular glaucoma in 36.4% of cases. The most frequent postoperative complications were choroidal detachment and hypotony.</div></div><div><h3>Conclusions</h3><div>Our data suggest that implantation of the Ahmed FP7 valve via pars plana is an effective and safe option for patients with refractory secondary glaucoma.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"99 10","pages":"Pages 420-426"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos De La Sociedad Espanola De Oftalmologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0365669124001060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To evaluate the success rate and complications of the Ahmed® FP7 valve implanted via Pars Plana in a group of vitrectomized patients with refractory glaucoma and anterior segment abnormalities from January 2018 to June 2023.

Methods

Quasi-experimental, prospective study. Eleven eyes with refractory glaucoma were included. Participants underwent a comprehensive ophthalmic examination, including assessment of intraocular pressure (IOP) reduction, visual acuity, characterization of glaucoma type, and number of antiglaucoma medications.

Results

The mean baseline IOP was 37.3 ± 11 mmHg, which decreased to 13.5 ± 3.0 mmHg after one year. The qualified success rate was 63.7%, while the complete success rate was 36.3%. The most common diagnosis was neovascular glaucoma in 36.4% of cases. The most frequent postoperative complications were choroidal detachment and hypotony.

Conclusions

Our data suggest that implantation of the Ahmed FP7 valve via pars plana is an effective and safe option for patients with refractory secondary glaucoma.

查看原文本刊更多论文

在难治性青光眼患者中通过眼旁植入 Ahmed® 瓣膜的效果

目的评估 2018 年 1 月至 2023 年 6 月期间，在一组玻璃体切除术后的难治性青光眼和眼前节异常患者中，经由 Pars Plana 植入 Ahmed® FP7 瓣膜的成功率和并发症。共纳入 11 名患有难治性青光眼的患者。参与者接受了全面的眼科检查，包括评估眼压（IOP）降低情况、视力、青光眼类型特征以及抗青光眼药物的数量。结果平均基线眼压为 37.3 ± 11 mmHg，一年后降至 13.5 ± 3.0 mmHg。合格成功率为 63.7%，完全成功率为 36.3%。最常见的诊断是新生血管性青光眼，占 36.4%。结论我们的数据表明，对于难治性继发性青光眼患者来说，通过眼旁植入 Ahmed FP7 瓣膜是一种有效而安全的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archivos De La Sociedad Espanola De Oftalmologia Medicine-Ophthalmology

CiteScore

1.20

自引率

0.00%

发文量

109

审稿时长

78 days

期刊介绍： La revista Archivos de la Sociedad Española de Oftalmología, editada mensualmente por la propia Sociedad, tiene como objetivo publicar trabajos de investigación básica y clínica como artículos originales; casos clínicos, innovaciones técnicas y correlaciones clinicopatológicas en forma de comunicaciones cortas; editoriales; revisiones; cartas al editor; comentarios de libros; información de eventos; noticias personales y anuncios comerciales, así como trabajos de temas históricos y motivos inconográficos relacionados con la Oftalmología. El título abreviado es Arch Soc Esp Oftalmol, y debe ser utilizado en bibliografías, notas a pie de página y referencias bibliográficas.